, Suivi des réponses aux traitements -patients ITK répondeurs. RC : Réponse Cytogénétique, vol.2
, Critères de réponse selon ELN 2013 et ESMO : 1 =réponse optimale ; 2 = en alerte ; 3 = en échec, RMM : Réponse Moléculaire Majeure
, RC : Réponse Cytogénétique (m : mineure ; P : partielle ; C : complète) ; RMM : Réponse Moléculaire Majeure. Critères de réponse selon ELN 2013 et ESMO : 1 =réponse optimale ; 2 = en alerte ; 3 = en échec, Suivi des réponses aux traitements -patients ITK non répondeurs ou intolérants 1 ère ligne de traitement, vol.3
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood. 19 mai, vol.127, issue.20, pp.2391-405, 2016. ,
A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining, Nature. juin, vol.243, issue.5405, pp.290-293, 1973. ,
Fused transcript of abl and bcr genes in chronic myelogenous leukaemia, Nature. juin, vol.315, issue.6020, pp.550-554, 1985. ,
Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years, Br J Haematol, vol.167, issue.1, pp.33-47, 2014. ,
Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study, vol.124, pp.2408-2418, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01064577
Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial, J Clin Oncol Off J Am Soc Clin Oncol. 10 juill, vol.29, issue.20, pp.2827-2859, 2011. ,
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS), Blood, vol.116, pp.3758-65, 2010. ,
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia, N Engl J Med, vol.09, issue.10, pp.917-944, 2017. ,
Estimation nationale de l'incidence des cancers en France entre, Lancet Lond Engl. 28 juill, vol.370, issue.9584, 1980. ,
, / Maladies chroniques et traumatismes / Rapports et synthèses / Publications et outils / Accueil
Epidemiology of chronic myeloid leukaemia (CML), Best Pract Res Clin Haematol. sept, vol.22, issue.3, pp.295-302, 2009. ,
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population, J Clin Oncol Off J Am Soc Clin Oncol, vol.20, issue.24, pp.2851-2858, 2016. ,
La leucémie myéloïde chronique de l'enfant et de l'adolescent : caractéristiques biologiques et cliniques au diagnostic, vol.07, p.3, 2017. ,
Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation, Hematol Am Soc Hematol Educ Program, vol.2010, pp.368-76, 2010. ,
Selective induction of leukemia-associated fusion genes by high-dose ionizing radiation, Cancer Res. 1 févr, vol.58, issue.3, pp.421-426, 1998. ,
The minute chromosome (Phl) in chronic granulocytic leukemia, Blut. avr, vol.8, pp.65-71, 1962. ,
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22, Cell. janv, vol.36, issue.1, pp.93-102, 1984. ,
,
, Bull Cancer (Paris). déc, vol.98, issue.12, pp.1403-1421, 2011.
Characterizing of Four Common BCR-ABL Kinase Domain Mutations (T315I, Y253H, M351T and E255K) in Iranian Chronic Myelogenous Leukemia Patients With Imatinib Resistance, Iran J Cancer Prev. mai, vol.8, issue.3, p.2334, 2015. ,
Leucémie myéloïde chronique ,
,
Treatment and molecular monitoring update in chronic myeloid leukemia management, Ann Biol Clin, issue.2, pp.129-145 ,
The molecular biology of chronic myeloid leukemia, vol.96, 2000. ,
Exon-skipping in BCR/ABL is induced by ABL exon 2, Biochem J. 15 mai, vol.348, pp.63-72, 2000. ,
ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia, Oncogene. déc, vol.21, issue.56, pp.8547-59, 2002. ,
Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia, Nature. 23 juill, vol.328, issue.6128, pp.342-346, 1987. ,
,
Akt and BCR-ABL in cell cycle progression and leukemogenesis, Leukemia. févr, vol.18, issue.2, pp.189-218, 2004. ,
Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors, Mol Cell Biol. juill, vol.24, issue.14, pp.6172-83, 2004. ,
,
, Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway, Genes Dev. 15 mai, vol.12, issue.10, pp.1415-1439, 1998.
,
, BCR-ABL down-regulates the DNA repair protein DNA-PKcs, Blood. 1 avr, vol.97, issue.7, pp.2084-90, 2001.
Biologie de la protéine de fusion BCR-ABL : progrès récents, Hématologie. 14 mars, vol.8, issue.1, pp.35-45, 2002. ,
Fusion tyrosine kinases: a result and cause of genomic instability. Oncogene. 4 janv, vol.26, pp.11-20, 2007. ,
,
, European LeukemiaNet recommendations for the management of chronic myeloid leukemia, Blood. 8 août, vol.122, issue.6, pp.872-84, 2013.
Pediatric chronic myeloid ,
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group, J Natl Cancer Inst. 3 juin, vol.90, issue.11, pp.850-858, 1998. ,
Clinical and biological features at diagnosis in 40 children with chronic myeloid leukemia, Pediatrics. juill, vol.116, issue.1, pp.140-143, 2005. ,
The International Registry for Chronic Myeloid Leukemia (CML) in Children and Adolescents (I-CML-Ped-Study): Objectives and Preliminary Results, Blood, vol.120, issue.21, pp.3741-3741, 2012. ,
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy, Blood, vol.02, issue.22, pp.2742-50, 2016. ,
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet, J Clin Oncol. 10 déc, vol.27, issue.35, pp.6041-51, 2009. ,
, La PCR quantitative -Principe de la PCR quantitative
BCR-ABL rearrangements in children with Philadelphia chromosome-positive chronic myelogenous leukemia, Blood, vol.78, issue.9, pp.2407-2417, 1991. ,
Childhood CML in India: b2a2 transcript is more common than b3a2, Cancer Genet Cytogenet. août, vol.169, issue.1, pp.76-83, 2006. ,
Correlation of BCR/ABL transcript variants with patients' characteristics in childhood chronic myeloid leukaemia, Eur J Haematol. 1 févr, vol.82, issue.2, pp.112-120, 2009. ,
Prognostic discrimination in « good-risk » chronic granulocytic leukemia, Blood. avr, vol.63, issue.4, pp.789-99, 1984. ,
Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation, Blood. déc, vol.66, issue.6, pp.1352-1359, 1985. ,
A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group, J Natl Cancer Inst. 3 juin, vol.90, issue.11, pp.850-858, 1998. ,
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score, Blood. 21 juill, vol.118, issue.3, pp.686-92, 2011. ,
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia, Leukemia. janv, vol.30, issue.1, pp.48-56, 2016. ,
Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?, Ann Hematol. août, vol.94, issue.8, pp.1363-71, 2015. ,
Optimal management for pediatric chronic myeloid leukemia, Pediatr Int Off J Jpn Pediatr Soc. mars, vol.58, issue.3, pp.171-180, 2016. ,
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial, Lancet Oncol, vol.11, issue.11, pp.1029-1064, 2010. ,
Early treatment decisions with interferon-alfa therapy in early chronic-phase chronic myelogenous leukemia, J Clin Oncol Off J Am Soc Clin Oncol. mars, vol.16, issue.3, pp.882-891, 1998. ,
Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group, N Engl J Med. 24 juill, vol.337, issue.4, pp.223-232, 1997. ,
The response to imatinib and interferon-? is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase, Haematologica. 1 août, vol.95, issue.8, pp.1415-1424, 2010. ,
Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study, Lancet Haematol. janv, vol.2, issue.1, pp.37-46, 2015. ,
Long-term follow-up of Philadelphia chromosome-positive (Ph) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period, Semantic Scholar, vol.130, 2005. ,
,
Allogeneic bone marrow transplantation for chronic myeloid leukemia in childhood: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC), Bone Marrow Transplant, vol.32, issue.10, pp.993-1002, 2003. ,
Stem cell transplantation for chronic myeloid leukemia in children, Blood. 15 août, vol.102, issue.4, pp.1224-1255, 2003. ,
Fiveyear follow-up of patients receiving imatinib for chronic myeloid leukemia, N Engl J Med. 7 déc, vol.355, issue.23, pp.2408-2425, 2006. ,
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat Med. mai, vol.2, issue.5, pp.561-567, 1996. ,
Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era, Front Biosci J Virtual Libr. 1 janv, vol.11, pp.209-229, 2006. ,
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N Engl J Med. 5 avr, vol.344, issue.14, pp.1031-1038, 2001. ,
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia, N Engl J Med. 13 mars, vol.348, issue.11, pp.994-1004, 2003. ,
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, Leukemia. juin, vol.23, issue.6, pp.1054-61, 2009. ,
Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group, Pediatr Blood Cancer. 15 juill, vol.57, issue.1, pp.56-62, 2011. ,
Allongement de l'intervalle QT secondaire aux inhibiteurs des tyrosines-kinases, Oncologie. 1 janv, vol.18, issue.1, pp.47-54, 2016. ,
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standarddose imatinib in chronic myeloid leukemia, Blood. 15 avr, vol.109, issue.8, pp.3496-3505, 2007. ,
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study, Blood, vol.104, issue.9, pp.2655-60, 2004. ,
Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation, Leukemia. févr, vol.20, issue.2, pp.187-92, 2006. ,
Growth deceleration in children treated with imatinib for chronic myeloid leukaemia, Eur J Cancer Oxf Engl, vol.50, issue.18, pp.3206-3217, 1990. ,
,
Impact of LongTerm Exposure to the Tyrosine Kinase Inhibitor Imatinib on the Skeleton of Growing Rats, PLoS ONE ,
Dysregulation of bone remodeling by imatinib mesylate, Blood. 28 janv, vol.115, issue.4, pp.766-74, 2010. ,
Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment, Med Sci Monit Int Med J Exp Clin Res. déc, vol.18, issue.12, pp.721-728, 2012. ,
Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis, Pediatr Blood Cancer. juill, vol.60, issue.7, pp.1148-53, 2013. ,
Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer, vol.59, pp.840-845, 2012. ,
Nilotinib is superior to imatinib as first-line therapy of chronic myeloid leukemia: the ENESTnd study, Expert Rev Hematol. déc, vol.3, issue.6, pp.665-73, 2010. ,
Successful Nilotinib Treatment in a Child with Chronic Myeloid Leukemia, Case Rep Oncol, vol.3, issue.2015 ,
Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval), Drug Saf. mai, vol.36, issue.5, pp.295-316, 2013. ,
, Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques
Severe peripheral arterial disease during nilotinib therapy, J Natl Cancer Inst. 7 sept, vol.103, issue.2, pp.1347-1355, 2011. ,
,
, Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION), Blood. 2 févr, vol.119, issue.5, pp.1123-1132, 2012.
Dasatinib -clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia, Rev Bras Hematol E Hemoter, vol.33, issue.2, pp.131-140, 2011. ,
How I treat childhood CML, Blood. 23 févr, vol.119, issue.8, pp.1821-1851, 2012. ,
Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium, J Clin Oncol Off J Am Soc Clin Oncol. 1 mars, vol.29, issue.7, pp.839-883, 2011. ,
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium, J Clin Oncol Off J Am Soc Clin Oncol. 1 juill, vol.31, pp.2460-2468, 2013. ,
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial, Br J Haematol. janv, vol.168, issue.1, pp.69-81, 2015. ,
Dosage plasmatique des inhibiteurs de tyrosine kinase ,
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, Lancet Oncol. 1 mai, vol.17, issue.5, pp.612-633, 2016. ,
Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel, Crit Rev Oncol Hematol. 1 déc, vol.120, pp.52-61, 2017. ,
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1, J Med Chem. 27 sept, vol.61, issue.18, pp.8120-8155, 2018. ,
Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study, Cancer, vol.15, issue.10, pp.1791-1800, 2017. ,
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML, Leukemia. juill, vol.32, issue.7, pp.1643-56, 2018. ,
,
, Chronic Myeloid Leukaemia: ESMO Clinical Practice Guidelines | ESMO
How I monitor residual disease in chronic myeloid leukemia, Blood, vol.114, issue.16, pp.3376-81, 2009. ,
Management of positive Philadelphia chromosome leukemia with ABL point mutations : recommendations from the FI-LMC group, Hématologie. 1 janv, vol.16, issue.1, pp.65-79, 2010. ,
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet, J Clin Oncol Off J Am Soc Clin Oncol. 10 déc, vol.27, issue.35, pp.6041-51, 2009. ,
Monitoring and defining early response: Where to draw the line?, Best Pract Res Clin Haematol, vol.29, issue.3, pp.284-94, 2016. ,
,
Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia, Lancet Oncol, vol.8, issue.11, pp.1018-1047, 2007. ,
hOCT 1 and resistance to imatinib, Blood. 1 août, vol.106, issue.3, pp.1133-1137, 2005. ,
Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia, Blood. 1 sept, vol.112, issue.5, pp.2024-2031, 2008. ,
MDR1 gene polymorphisms and imatinib response in chronic myeloid leukemia: a meta-analysis, Pharmacogenomics. avr, vol.15, issue.5, pp.667-77, 2014. ,
Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression, Cancer Res. 1 déc, vol.68, issue.23, pp.9809-9825, 2008. ,
Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance, Blood. 1 août, vol.96, issue.3, pp.1070-1079, 2000. ,
DNA sequencing with chain-terminating inhibitors, Proc Natl Acad Sci. 1 déc, vol.74, issue.12, 1977. ,
Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor, Leuk Res. mars, vol.33, issue.3, pp.450-459, 2009. ,
Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia, Haematologica, vol.101, issue.7, pp.830-838, 2016. ,
Le séquençage d'ADN à haut débit en pratique clinique, Arch Pédiatrie. 1 avr, vol.24, issue.4, pp.373-83, 2017. ,
The impact of next-generation sequencing technology on genetics, Trends Genet TIG. mars, vol.24, issue.3, pp.133-174, 2008. ,
Guidelines for diagnostic next-generation sequencing, Eur J Hum Genet. janv, vol.24, issue.1, pp.2-5, 2016. ,
, Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study, Blood. 25 juill, vol.122, issue.4, pp.515-537, 2013. ,
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial, Lancet Oncol. juin, vol.19, issue.6, pp.747-57, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01859932
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study, Blood. 16 févr, vol.129, issue.7, pp.846-54, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02050833
Interferon in chronic myeloid leukaemia: past and future, Best Pract Res Clin Haematol. 1 sept, vol.22, issue.3, pp.315-344, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00441364
,
, BloodRef -hematology reference ? CML EUTOS score calculator
Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia -A, Europe Against Cancer Program. Leukemia. déc, vol.17, issue.12, pp.2318-57, 2003. ,
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia, Leukemia. mai, vol.29, issue.5, pp.999-1003, 2015. ,
Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line, Ann Hematol. 23 févr, 2019. ,
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance, Blood. 1 mai, vol.99, issue.9, pp.3472-3477, 2002. ,
Chronic myeloid leukemia and interferon-?: a study of complete cytogenetic responders, Blood, vol.15, issue.10, 2001. ,
Irradiation corporelle totale: techniques, dosimétrie et complications, Cancer/Radiothérapie. 1 mars, vol.3, issue.2, pp.162-71, 1999. ,
Nilotinib Treatment in Pediatric Patients (pts) with Philadelphia Chromosome-Positive (Ph+) Leukemia Refractory to Prior Tyrosine Kinase Inhibitor (TKI) Therapy: Results from Nilotinib Compassionate Use Program, Blood, vol.112, issue.11, pp.4264-4264, 2008. ,
Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents, Haematologica, vol.102, issue.10, pp.1704-1712, 2017. ,
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study, Blood. 28 mai, vol.113, issue.22, pp.5401-5412, 2009. ,
Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib, J Clin Oncol. 12 avr, vol.28, issue.14, pp.2381-2389, 2010. ,
Leucémie myéloïde chronique : étude critique des essais thérapeutiques de l'interféron-alpha recombinant et analyse des facteurs de pronostic, Hématologie. 23 juill, vol.5, issue.3, pp.225-257, 1999. ,
, en présence des maîtres de la Faculté
ceux qui m'ont instruit dans les préceptes de mon art et de leur témoigner ma reconnaissance en restant fidèle à leur enseignement ,
, intérêt de la santé publique, ma profession avec conscience et de respecter non seulement la législation en vigueur, mais aussi les règles de l'honneur
, Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque